Search

The atopic patient also suffers from non-allergic comorbidities whose impact on response to systemic treatments has rarely been evaluated in clinical practice.3 Among these, data on the impact of metabolic and psychiatric comorbidities in the response to dupilumab are scarce. Impact of comorbidities in the response of atopic patients treated with dupilumab: a real-life study up to 36 weeks 19 patients have no comorbidity at baseline vs. 22, this difference was not significant ( I P i = 0.5), similar results were observed when considering only patients with allergic comorbidities ( I P i = 0.22). [Extracted from the article]